FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280604292> ?p ?o ?g. }

• W4280604292 endingPage "1461" @default.
• W4280604292 startingPage "1449" @default.
• W4280604292 abstract "This clinical trial assessed the activity of reproxalap, a novel reactive aldehyde species modulator, and estimated clinically relevant thresholds for changes in ocular itching and redness in an allergic conjunctivitis field trial. This was a randomized, double-masked, vehicle-controlled phase 2 trial. Patients with ragweed-associated allergic conjunctivitis were assessed over 28 days in an environmental setting with approximately four doses per day of either 0.25% reproxalap, 0.5% reproxalap, or vehicle. Patients recorded ocular itching, redness, tearing, and eyelid swelling scores (each with a 0–4 scale, except for a 0–3 scale for swelling), and completed the Allergic Conjunctivitis Quality of Life Questionnaire at the beginning and end of the trial. Mixed model of repeated measures analysis demonstrated statistically lower itching and tearing scores (pooled P = 0.026 and P < 0.001, respectively) and numerically lower redness and eyelid swelling scores than vehicle on days when pollen exceeded the 95th percentile value. Using three anchor-based and three distribution-based approaches, the meaningful within-patient change and the between-group meaningful difference for patient-reported ocular itching and redness was estimated to be approximately 0.5. The most common treatment-emergent adverse event associated with reproxalap was transient irritation upon instillation. In a field clinical trial, reproxalap was well tolerated and superior to vehicle in reducing ocular itching on high-pollen days. The clinical meaningfulness threshold estimates of 0.5 units are among the first such calculations generated for the standard ocular itching and redness scores, providing important context for the clinical interpretation of clinical trials in allergic conjunctivitis. While allergic conjunctivitis affects millions of patients worldwide, treatments with new mechanisms have not been introduced in decades. Reproxalap, a medicine being investigated as a treatment for allergic conjunctivitis, works by regulating reactive aldehyde species—molecules that are increased in a variety of inflammatory diseases. This clinical trial assessed the activity of reproxalap and estimated what amount of change in ocular itching and redness should be considered clinically important. Patients with ragweed-associated allergic conjunctivitis were assessed over 28 days and were given one of three possible eye drops at approximately four doses per day: 0.25% reproxalap; 0.5% reproxalap; or vehicle, which was composed of the same ingredients but does not contain reproxalap. Patients recorded ocular itching, redness, tearing, and eyelid swelling (all scales ranged from 0 [none] to 4 [severe] except for eyelid swelling, which ranged from 0 to 3), and completed a quality-of-life questionnaire on allergic conjunctivitis at the beginning and end of the trial. The results indicated that reproxalap was significantly better than vehicle in reducing itching and tearing scores and was better than vehicle in reducing redness and eyelid swelling scores on days when pollen counts were high. The trial also suggested that a reduction in ocular itching and redness scores of approximately 0.5 or more (scale 0–4) is likely to be clinically important. Overall, reproxalap was well tolerated and no safety concerns were noted. The most common side effect was transient ocular discomfort after eye drop administration." @default.
• W4280604292 created "2022-05-22" @default.
• W4280604292 creator A5025768648 @default.
• W4280604292 creator A5039408126 @default.
• W4280604292 creator A5079979065 @default.
• W4280604292 creator A5085096603 @default.
• W4280604292 creator A5089059766 @default.
• W4280604292 date "2022-05-18" @default.
• W4280604292 modified "2023-09-25" @default.
• W4280604292 title "Reproxalap Activity and Estimation of Clinically Relevant Thresholds for Ocular Itching and Redness in a Randomized Allergic Conjunctivitis Field Trial" @default.
• W4280604292 cites W1481600494 @default.
• W4280604292 cites W1630835083 @default.
• W4280604292 cites W1637900354 @default.
• W4280604292 cites W1967126262 @default.
• W4280604292 cites W1977733462 @default.
• W4280604292 cites W1980498795 @default.
• W4280604292 cites W1981528056 @default.
• W4280604292 cites W2000657166 @default.
• W4280604292 cites W2015424039 @default.
• W4280604292 cites W2017033164 @default.
• W4280604292 cites W2141716244 @default.
• W4280604292 cites W2153819462 @default.
• W4280604292 cites W2171502725 @default.
• W4280604292 cites W2197385979 @default.
• W4280604292 cites W2269916092 @default.
• W4280604292 cites W2271763856 @default.
• W4280604292 cites W2327324808 @default.
• W4280604292 cites W3087057562 @default.
• W4280604292 cites W3124533858 @default.
• W4280604292 cites W3126967770 @default.
• W4280604292 cites W3158372551 @default.
• W4280604292 cites W4225987075 @default.
• W4280604292 doi "https://doi.org/10.1007/s40123-022-00520-z" @default.
• W4280604292 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35585427" @default.
• W4280604292 hasPublicationYear "2022" @default.
• W4280604292 type Work @default.
• W4280604292 citedByCount "1" @default.
• W4280604292 countsByYear W42806042922023 @default.
• W4280604292 crossrefType "journal-article" @default.
• W4280604292 hasAuthorship W4280604292A5025768648 @default.
• W4280604292 hasAuthorship W4280604292A5039408126 @default.
• W4280604292 hasAuthorship W4280604292A5079979065 @default.
• W4280604292 hasAuthorship W4280604292A5085096603 @default.
• W4280604292 hasAuthorship W4280604292A5089059766 @default.
• W4280604292 hasBestOaLocation W42806042921 @default.
• W4280604292 hasConcept C118487528 @default.
• W4280604292 hasConcept C126322002 @default.
• W4280604292 hasConcept C141071460 @default.
• W4280604292 hasConcept C16005928 @default.
• W4280604292 hasConcept C168563851 @default.
• W4280604292 hasConcept C197934379 @default.
• W4280604292 hasConcept C203014093 @default.
• W4280604292 hasConcept C207480886 @default.
• W4280604292 hasConcept C2779923671 @default.
• W4280604292 hasConcept C2780238520 @default.
• W4280604292 hasConcept C2780870513 @default.
• W4280604292 hasConcept C2781302119 @default.
• W4280604292 hasConcept C535046627 @default.
• W4280604292 hasConcept C71924100 @default.
• W4280604292 hasConceptScore W4280604292C118487528 @default.
• W4280604292 hasConceptScore W4280604292C126322002 @default.
• W4280604292 hasConceptScore W4280604292C141071460 @default.
• W4280604292 hasConceptScore W4280604292C16005928 @default.
• W4280604292 hasConceptScore W4280604292C168563851 @default.
• W4280604292 hasConceptScore W4280604292C197934379 @default.
• W4280604292 hasConceptScore W4280604292C203014093 @default.
• W4280604292 hasConceptScore W4280604292C207480886 @default.
• W4280604292 hasConceptScore W4280604292C2779923671 @default.
• W4280604292 hasConceptScore W4280604292C2780238520 @default.
• W4280604292 hasConceptScore W4280604292C2780870513 @default.
• W4280604292 hasConceptScore W4280604292C2781302119 @default.
• W4280604292 hasConceptScore W4280604292C535046627 @default.
• W4280604292 hasConceptScore W4280604292C71924100 @default.
• W4280604292 hasFunder F4320319310 @default.
• W4280604292 hasIssue "4" @default.
• W4280604292 hasLocation W42806042921 @default.
• W4280604292 hasLocation W42806042922 @default.
• W4280604292 hasLocation W42806042923 @default.
• W4280604292 hasOpenAccess W4280604292 @default.
• W4280604292 hasPrimaryLocation W42806042921 @default.
• W4280604292 hasRelatedWork W2004935574 @default.
• W4280604292 hasRelatedWork W2110853721 @default.
• W4280604292 hasRelatedWork W2128179053 @default.
• W4280604292 hasRelatedWork W2817320137 @default.
• W4280604292 hasRelatedWork W2982259878 @default.
• W4280604292 hasRelatedWork W3215550076 @default.
• W4280604292 hasRelatedWork W4254794078 @default.
• W4280604292 hasRelatedWork W4283778972 @default.
• W4280604292 hasRelatedWork W4385765412 @default.
• W4280604292 hasRelatedWork W2463878879 @default.
• W4280604292 hasVolume "11" @default.
• W4280604292 isParatext "false" @default.
• W4280604292 isRetracted "false" @default.
• W4280604292 workType "article" @default.